Get the Stockscreener App
0.6915
9.13%
-0.0695
Pre-market:
.69
-0.0015
-0.22%
Inmed Pharmaceuticals Inc stock is traded at $0.6915, with a volume of 175.56K.
It is down -9.13% in the last 24 hours and down -21.42% over the past month.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.
See More
Previous Close:
$0.761
Open:
$0.759
24h Volume:
175.56K
Relative Volume:
1.45
Market Cap:
$2.02M
Revenue:
$4.51M
Net Income/Loss:
$-7.66M
P/E Ratio:
-0.183
EPS:
-3.778
Net Cash Flow:
$-7.51M
1W Performance:
-22.30%
1M Performance:
-21.42%
6M Performance:
-68.28%
1Y Performance:
-75.74%
1-Day Range:
$0.65
$0.759
1-Week Range:
$0.65
$0.91
52-Week Range:
$0.65
$7.98
Inmed Pharmaceuticals Inc Stock (INM) Company Profile
Name
Inmed Pharmaceuticals Inc
Sector
Phone
(604) 669-7207
Address
1445-885 WEST GEORGIA ST., VANCOUVER
Compare INM vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INM
Inmed Pharmaceuticals Inc
|
0.6915 | 2.02M | 4.51M | -7.66M | -7.51M | -3.778 |
TAK
Takeda Pharmaceutical Co Adr
|
18.04 | 56.99B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
115.93 | 48.94B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.30B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.14 | 33.94B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
531.82 | 23.31B | 3.18B | 1.33B | 1.04B | 27.90 |
Inmed Pharmaceuticals Inc Stock (INM) Latest News
InMed reports preclinical data on Alzheimer’s drug candidate By Investing.com - Investing.com Australia
InMed Pharmaceuticals Inc.Common Shares (NQ: INM - The Chronicle-Journal
InMed Pharmaceuticals Reports Positive INM-901 Data in Human Brain Organoid Models for Alzheimer’s Disease Program 12 - Minichart
InMed Pharmaceuticals Inc. (INM) Stock: Shows Promising Anti-Inflammatory Effects in 3D Brain Organoid Study - parameter.io
InMed Pharmaceuticals (INM) Advances Alzheimer's Research with N - GuruFocus
InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program - Investing News Network
InMed Reports Positive Preclinical Data for Alzheimer’s Candidate - TipRanks
InMed reports preclinical data on Alzheimer’s drug candidate - Investing.com
InMed Pharmaceuticals Inc recently released positive research data for its Alzheimer's disease treatment project INM-901, according to documents submitted to the U.S. Securities and Exchange Commission (SEC). - Bitget
InMed (NASDAQ: INM) reports INM-901 organoid data, targets Phase 1 in 2027 - Stock Titan
Lab-grown human brain tissue backs InMed’s Alzheimer’s drug ahead of trials - Stock Titan
Aug Decliners: Can InMed Pharmaceuticals Inc outperform under higher oil pricesWeekly Market Outlook & Low Drawdown Trading Strategies - baoquankhu1.vn
[S-3] InMed Pharmaceuticals Inc. Shelf Registration Statement | INM SEC FilingForm S-3 - Stock Titan
Aug Weekly: Can InMed Pharmaceuticals Inc be the next market leaderBear Alert & Accurate Entry/Exit Alerts - baoquankhu1.vn
Ideas Watch: Can InMed Pharmaceuticals Inc be the next market leader2026 Institutional Moves & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Published on: 2026-03-17 19:00:00 - baoquankhu1.vn
CEO Moves: Will InMed Pharmaceuticals Inc stock go up in YEAR2026 Review & AI Enhanced Execution Alerts - baoquankhu1.vn
12 Health Care Stocks Moving In Monday's After-Market Session - Sahm
InMed Pharmaceuticals Advances INM-901 for Alzheimer’s and INM-089 for Macular Degeneration with FDA Engagement Planned for 2026-2027 1 - Minichart
InMed Pharmaceuticals (INM) Sets 2026 Development Goals - GuruFocus
InMed Provides Update on Pharmaceutical Development ProgramsAdvancing Lead Drug Candidates Towards IND and Clinical Trial - Investing News Network
InMed outlines 2026 development plans for lead programs - TipRanks
InMed Provides 2026 Development Outlook; Targets FDA pre-IND for INM-901 and Phase 1 in 2027 - TradingView
InMed (INM) sets 2026 goals for Alzheimer’s and eye-disease drug programs - Stock Titan
InMed's 2026 push to bring Alzheimer's, eye drug candidates to human testing - Stock Titan
Can InMed Pharmaceuticals Inc reach all time highs this yearJuly 2025 Technicals & Weekly Momentum Picks - baoquankhu1.vn
InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline - Investing News Network
According to the latest filing disclosed by the U.S. Securities and Exchange Commission (SEC), InMed Pharmaceuticals Inc (INM) officially confirmed and passed a resolution on March 4 to gradually terminate the commercial operations of its Baymedica divisio - Bitget
InMed Pharmaceuticals Exits BayMedica to Refocus on Pipeline - TipRanks
InMed Pharmaceuticals IncOn March 4, Co Confirmed And Approved The Decision To Wind Down Baymedica's Commercial OperationsSEC Filing - TradingView
InMed (NASDAQ: INM) winds down BayMedica unit and pivots fully to drug development - Stock Titan
INM Should I Buy - Intellectia AI
INM Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Can InMed Pharmaceuticals Inc. reach all time highs this yearQuarterly Performance Summary & Technical Confirmation Trade Alerts - mfd.ru
Risk Off: Can InMed Pharmaceuticals Inc be the next market leaderMarket Trend Report & Daily Volume Surge Signals - baoquankhu1.vn
Published on: 2026-02-27 15:19:59 - baoquankhu1.vn
Is InMed Pharmaceuticals Inc. undervalued by DCF analysis2025 Bull vs Bear & Safe Capital Growth Stock Tips - mfd.ru
Is InMed Pharmaceuticals Inc. (MWG) stock a contrarian opportunity2025 Market Outlook & Safe Entry Momentum Tips - mfd.ru
INM Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Aug Movers: Is InMed Pharmaceuticals Inc undervalued by DCF analysisMarket Weekly Review & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
InMed Highlights Q2 Results Amid Cash, Regulatory Pressures - TipRanks
InMed Pharmaceuticals Inc Reports Q2 2026 Financial Results and Business Update - TradingView
InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update - Investing News Network
InMed Pharmaceuticals Inc. SEC 10-Q Report - TradingView
What analysts say about InMed Pharmaceuticals Inc. stockJuly 2025 Fed Impact & Verified Stock Trade Ideas - mfd.ru
What drives InMed Pharmaceuticals Inc.’s stock priceGlobal Markets & Verified Entry Point Detection - mfd.ru
Will InMed Pharmaceuticals Inc stock go up in YEAR2025 Key Highlights & Safe Entry Zone Identification - baoquankhu1.vn
Nasdaq Moves: What analysts say about InMed Pharmaceuticals Inc stockTrend Reversal & Growth Focused Investment Plans - baoquankhu1.vn
Can InMed Pharmaceuticals Inc. stock double in the next yearJuly 2025 Fed Impact & Weekly High Conviction Trade Ideas - mfd.ru
Aug Summary: Will InMed Pharmaceuticals Inc. stock go up in YEARJuly 2025 Selloffs & Weekly Chart Analysis and Guides - mfd.ru
Should I add InMed Pharmaceuticals Inc. stock to my portfolio2025 Geopolitical Influence & Weekly High Return Stock Opportunities - mfd.ru
Inmed Pharmaceuticals Inc Stock (INM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
1.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):